PPARG and metabolic dysfunction-associated steatotic liver disease: In line, heterozygous PPARγ-deficient mice developed more severe MCD-induced NAFLD, whereas treatment with PPARγ agonists, including rosiglitazone and pioglitazone, prevented the development of NAFLD with fibrosis [16,17,18,19].